SCHEMBL1574797

SCHEMBL1574797

CC(=O)c1c(-c2ccccc2)nn(C)c1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
CSF1R P07333 1/20 0.62
FGFR1 P11362 1/20 0.62
FLT1 P17948 1/20 0.62
KDR P35968 1/20 0.62
CSNK1A1 P48729 1/20 0.62
CDK8 P49336 1/20 0.62
GSK3A P49840 1/20 0.62
GSK3B P49841 1/20 0.62
CDK5 Q00535 1/20 0.62
PRKCQ Q04759 1/20 0.62
LRRK2 Q5S007 1/20 0.62
CLK4 Q9HAZ1 1/20 0.62
DYRK1B Q9Y463 1/20 0.62
KMT2A Q03164 2/20 0.60
RECQL P46063 2/20 0.55
POLB P06746 1/20 0.52
NPSR1 Q6W5P4 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17142715 0.89 CYP1A2 (0.64) CYP1A2CYP2C9CYP2C19CSF1RFGFR1
SCHEMBL8888266 0.83 CSF1R (0.66) CYP1A2CYP2C9CYP2C19CSF1RFGFR1
SCHEMBL17295334 0.82 CSF1R (0.64) CYP1A2CYP2C9CYP2C19CSF1RFGFR1
SCHEMBL17290901 0.82 CSF1R (0.64) CYP1A2CYP2C9CYP2C19CSF1RFGFR1
SCHEMBL15656069 0.81 KDR (0.71) CYP1A2CYP2C9CYP2C19CSF1RFGFR1
SCHEMBL4707932 0.77 CDK8 (1.00) CSF1RFGFR1FLT1KDRCSNK1A1
SCHEMBL266137 0.74 RECQL (0.58) CYP1A2CYP2C9CYP2C19KMT2ARECQL
SCHEMBL9956863 0.73 KMT2A (0.67) CYP1A2CYP2C9CYP2C19CSF1RFGFR1
SCHEMBL14592091 0.73 CSF1R (0.47) CYP1A2CYP2C9CYP2C19CSF1RFGFR1
SCHEMBL12997973 0.72 KDR (0.60) CYP1A2CYP2C9CYP2C19CSF1RFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751149-B1 BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS ABBOTT LAB (US) 2012-06-06 EP disclosed
EP-2308873-A1 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents Abbott Laboratories (US) 2011-04-13 EP disclosed
EP-1751149-A1 BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS ABBOTT LABORATORIES (US) 2007-02-14 EP disclosed
US-7098222-B2 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents ABBOTT LABORATORIES (US) 2006-08-29 US disclosed
US-20050272728-A1 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents ABBVIE INC. 2005-12-08 US disclosed
WO-2005113551-A1 BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS ABBOTT LABORATORIES (US) 2005-12-01 WO disclosed
US-20050256118-A1 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents ABBOTT LABORATORIES 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272728-A1 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents HRH3, HRH4, HRH2 CYP1A2 591/4885CYP2C9 972/4885CYP2C19 571/4885
US-20050256118-A1 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents HRH3, HRH4, HRH2 CYP1A2 591/4885CYP2C9 972/4885CYP2C19 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.